

INTERLEUKIN GENETICS INC  
Form 8-K  
July 02, 2004

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported): **July 1, 2004**

### Interleukin Genetics, Inc.

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation)

**000-23413**  
(Commission  
File Number)

**94-3123681**  
(IRS Employer  
Identification No.)

**135 Beaver Street, Waltham, MA 02452**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(781) 398-0700**



**Item 5. Other Events.**

On July 1, 2004, Interleukin Genetics, Inc. publicly disseminated a press release announcing that it had signed a Research Agreement with Access Business Group LLC, a subsidiary of Alticor Inc., to conduct research into the development of a test to identify individuals with specific genetic variations that affect how people gain and maintain weight.

The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.

**Item 7. Financial Statements and Exhibits.**

(c) Exhibits

99.1 Press Release dated July 1, 2004

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Interleukin Genetics, Inc.  
(Registrant)

Date: July 2, 2004

**/s/ Fenel M. Eloi**  
**Fenel M. Eloi**  
**Chief Operating Officer,**  
**Chief Financial Officer,**  
**Treasurer and Secretary**